NA
IRD

NewEdge Advisors’s Opus Genetics IRD Stock Holding History

NewEdge Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.5K Hold
16,364
– – ﹤0.01% 2837
2025
Q4 		$32.9K Hold
16,364
– – ﹤0.01% 3096
2025
Q3 		$27K Hold
16,364
– – ﹤0.01% 3023
2025
Q2 		$15.4K Buy
+16,364
New +$15.2K ﹤0.01% 3042
2024
Q1 		– Sell
-19
Closed -$57 – 3980
2023
Q4 		$57 Buy
+19
New +$56 ﹤0.01% 3663

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NewEdge Advisors's IRD Position: Q1 2026 in Review

NewEdge Advisors held its Opus Genetics (IRD) position steady in Q1 2026 at 16,364 shares worth $74.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

NewEdge Advisors first reported a position in IRD in Q4 2023 and has held it in 5 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • NewEdge Advisors held 16,364 shares of Opus Genetics worth $74.5K as of Q1 2026.
  • NewEdge Advisors left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2837 holding.
  • NewEdge Advisors first reported a position in Opus Genetics in Q4 2023 and has held it in 5 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.